# US 2026/0074019 A1 · Approaches to discovering, analyzing, and synthesizing compounds through automated in silico experimentation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0074019 A1
- Document ID: US20260074019A1
- Status: Published application
- Kind: A1
- Application number: 19/080,717
- Filed: 2025-03-14
- Published: 2026-03-12
- Earliest claimed: 2022-09-15
- Assignees: Ligandal, Inc.
- Applicants: Ligandal, Inc.
- Inventors: Andre WATSON; Adam STEIN; Nash RAIGLE
- Web page: https://patentgrep.com/patent/US20260074019A1

## CPC

- G16B 35/10: Design of libraries
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- G06N 3/045: Combinations of networks
- G06N 3/092: Reinforcement learning
- G06N 10/20: Models of quantum computing, e.g. quantum circuits or universal quantum computers
- G06N 10/40: Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
- G06N 20/00: Machine learning
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 40/20: Supervised data analysis
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Introduced here is an approach to developing molecules and molecule groups via a simulated mutagenesis process that is performed as part of in silico experimentation. Due to its initiation of the simulation based on a known binding interface or predicted binding interface between two structures—whether biological or synthetic—with known sequences, the approach introduced here can accomplish linear iteration of sequences. This can be accomplished whether these sequences relate to proteins, biological amino acids, synthetic amino acids, biological nucleic acids, synthetic nucleic acids, unnatural variants thereof, or any other molecules with a three-dimensional (“3D”) structure to evaluate the thermodynamic binding and affinity of the interaction as individual nucleic acids, amino acids or individual units of a polymer are mutated one at a time.

## Claims

### Claim 1

A computing device comprising:
a processor;
a first module that, when executed by the processor, is configured to generate multiple peptide sequences based on cell type specificity, tissue specificity, or organ specificity, through the use of a first machine learning model that predicts protein-protein interactions;
a second module that, when executed by the processor, is configured to employ a second machine learning model to predict binding interfaces for the multiple peptide sequences;
a third module that, when executed by the processor, is configured to identify a peptide sequence from among the multiple peptide sequences based on an analysis of the predicted binding interfaces and data related to docking capabilities of the multiple peptide sequences;
a fourth module that, when executed by the processor, is configured to enhance one or more properties of a peptide represented by the peptide sequence through simulated mutagenesis of the peptide sequence; and
a fifth module that, when executed by the processor, is configured to generate instructions for instrumentation that is able to synthesize the mutated peptide sequence of the peptide.

### Claim 2 (depends on 1)

The computing device of claim 1, wherein the second machine learning model is based on a neural network that implements a reinforcement learning algorithm.

### Claim 3 (depends on 1)

The computing device of claim 1, wherein the binding interfaces are predicted between a series of ligands and a series of biological targets.

### Claim 4 (depends on 1)

The computing device of claim 1, further comprising:
a communication module that is configured to provide access to one or more databases containing data relating to proteins, cells, tissues, organs, structures, surfactomics, or proteomics.

### Claim 5 (depends on 1)

The computing device of claim 1, further comprising:
a sixth module that, when executed by the processor, is configured to generate visualizations that include information regarding the peptide sequence, so as to facilitate informed decision making with respect to development and synthesis of the peptide.

### Claim 6

A method for developing a peptide having a therapeutic application, the method comprising:
receiving input that is indicative of a selection of an organ, a tissue, or a cell type;
generating, based on the input, multiple amino acid sequences that are representative of multiple peptides;
predicting binding interfaces for each of the multiple peptides;
identifying, based on the binding interfaces, a given peptide from among the multiple peptides;
enhancing a property of the given peptide through simulated single-point mutagenesis across an interacting surface of the given peptide; and
documenting the given peptide, with the enhanced property, by storing information in a data structure.

### Claim 7 (depends on 6)

The method of claim 6, wherein said generating comprises:
identifying a dataset that includes information regarding the selected organ, tissue, or cell type, and
applying, to the dataset, a machine learning model that predicts protein-protein interactions for each of the different peptides.

### Claim 8 (depends on 7)

The method of claim 7, wherein the machine learning model is trained on another dataset that includes information regarding known protein-protein interactions determined through x-ray crystallography data or cryo-electron microscopy data.

### Claim 9 (depends on 6)

The method of claim 6, further comprising:
transmitting the data structure to instrumentation to prompt synthesis of the given peptide.

### Claim 10 (depends on 6)

The method of claim 6, wherein the property is energetics, solubility, binding affinity, or delivery mechanism.

### Claim 11

A non-naturally occurring peptide ligand of CD34 comprising or consisting of an amino acid sequence at least about 80%, 85%, 90%, 95%, 99%, or 100% identical to a sequence selected from the group consisting of SEQ ID NO: 1-85.

### Claim 12 (depends on 11)

The non-naturally occurring peptide ligand of CD34 of claim 11, wherein the non-naturally occurring peptide ligand of CD34 comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-85.

### Claim at position 13

13-182. (canceled)
